Disease · MONDO_0002400

synovitis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. synovitis. Diseases, record MONDO_0002400. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0002400

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: synovitis; Open Targets
Open Targets ID: MONDO_0002400; Open Targets
Other names: Synovial Hypertrophy, Synovial Thickening, inflammation of synovial membrane of synovial joint, synovial membrane of synovial joint inflammation, synovitis (disease); Open Targets
Disease Ontology: DOID:2703; Disease Ontology
MeSH: D013585; MeSH
NCI Thesaurus: C50766; NCI Thesaurus
Highest stage of its drugs: Approval, for 5 of its 12 drugs, from DailyMed; Open Targets

Drugs12

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CORTISONE ACETATE	CHEMBL1650	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
DEXAMETHASONE	CHEMBL384467	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
DEXAMETHASONE SODIUM PHOSPHATE	CHEMBL2021430	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
PREDNISOLONE	CHEMBL131	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
PREDNISONE	CHEMBL635	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
ANAKINRA	CHEMBL1201570	Protein	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
BETAMETHASONE	CHEMBL632	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
ETORICOXIB	CHEMBL416146	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
METHOTREXATE	CHEMBL34259	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
LUTIKIZUMAB	CHEMBL4594518	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 12

See all 12 drugs

Targets6

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	7	Glucocorticoid receptor agonist	Approval	https://conductscience.org/library/genes/2908	Drugs and targets
DHFR	Dihydrofolate reductase	1	Dihydrofolate reductase inhibitor	Phase 2	https://conductscience.org/library/genes/1719	Drugs and targets
IL1A	Interleukin-1 alpha	1	Interleukin-1 alpha inhibitor	Phase 2	https://conductscience.org/library/genes/3552	Drugs and targets
IL1B	Interleukin-1 beta	1	Interleukin-1 beta inhibitor	Phase 2	https://conductscience.org/library/genes/3553	Drugs and targets
IL1R1	Interleukin-1 receptor type 1	1	Interleukin-1 receptor antagonist	Phase 3	https://conductscience.org/library/genes/3554	Drugs and targets
PTGS2	Prostaglandin G/H synthase 2	1	Cyclooxygenase-2 inhibitor	Phase 3	https://conductscience.org/library/genes/5743	Drugs and targets

Trials6

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02087904	A Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981 in Patients With Knee Osteoarthritis	Phase 2	350	2019-08-28	Knee Osteoarthritis, Medial Compartment Knee Osteoarthritis	LUTIKIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT03167333	The Role of Synovitis in Osteoarthritis	Not applicable	100		Synovitis of Knee, Osteoarthritis, Knee	HYALURONIC ACID	Its record names the disease	ClinicalTrials.gov
NCT07328022	Efficacy and Safety of Etoricoxib/Betamethasone Combination in Acute Bursitis, Tendinitis and Synovitis	Phase 3	89		Bursitis, Tendinitis, Synovitis	BETAMETHASONE, ETORICOXIB	Its record names the disease	ClinicalTrials.gov
NCT07161336	Role of Methotrexate in Ultrasound Proven Synovitis in Primary Knee OA	Phase 2	70		Osteo Arthritis of the Knee, Synovitis of Knee, Methotrexate	METHOTREXATE	Its record names the disease	ClinicalTrials.gov
NCT01705756	Kineret (Anakinra), in Adult Patients With Colchicine-Resistant Familial Mediterranean Fever	Phase 3	25		Familial Mediterranean Fever	ANAKINRA	Its record names the disease	ClinicalTrials.gov
NCT03355482	MRI Evaluation Assessing Synovitis to Address the Unmet Need for Reliable Endpoints in SLE	Phase 2	9		Systemic Lupus Erythematosus Arthritis	METHOTREXATE, METHYLPREDNISOLONE	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials2

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
30653843	DERIVED	1	PubMed
27860460	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0002400

GET https://conductscience.org/api/diseases/v1/MONDO_0002400/drugs

API reference For AI assistants